Saol Therapeutics, Inc.
🇺🇸United States
Expanded Access Treatment Protocol With DCA for Patients With PDCD
- Conditions
- Pyruvate Dehydrogenase Complex Deficiency
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Saol Therapeutics Inc
- Registration Number
- NCT06931262
Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain
Phase 2
Active, not recruiting
- Conditions
- Osteoarthritis, Knee Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Saol Therapeutics Inc
- Target Recruit Count
- 132
- Registration Number
- NCT05470608
- Locations
- 🇺🇸
Prime Medical Research, Coral Gables, Florida, United States
🇺🇸Denver Spine & Pain Institute, Greenwood Village, Colorado, United States
🇺🇸Pacific Sports and Spine, Eugene, Oregon, United States
Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Saol Therapeutics Inc
- Target Recruit Count
- 32
- Registration Number
- NCT05311215
- Locations
- 🇺🇸
TIRR Memorial Hermann Research Center, Houston, Texas, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:
Phase 3
Active, not recruiting
- Conditions
- Pyruvate Dehydrogenase Complex Deficiency
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Saol Therapeutics Inc
- Target Recruit Count
- 34
- Registration Number
- NCT02616484
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Stanford University, Stanford, California, United States
© Copyright 2025. All Rights Reserved by MedPath